Insulin-stimulated cardiac glucose oxidation is increased in high-fat diet-induced obese mice lacking malonyl CoA decarboxylase
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Whereas an impaired ability to oxidize fatty acids is thought to contribute to intracellular lipid accumulation, insulin resistance, and cardiac dysfunction, high rates of fatty acid oxidation could also impair glucose metabolism and function. We therefore determined the effects of diet-induced obesity (DIO) in wild-type (WT) mice and mice deficient for malonyl CoA decarboxylase (MCD−/−; an enzyme promoting mitochondrial fatty acid oxidation) on insulin-sensitive cardiac glucose oxidation. RESEARCH DESIGN AND METHODS: WT and MCD−/− mice were fed a low- or high-fat diet for 12 weeks, and intramyocardial lipid metabolite accumulation was assessed. A parallel feeding study was performed to assess myocardial function and energy metabolism (nanomoles per gram of dry weight per minute) in isolated working hearts (+/– insulin). RESULTS: DIO markedly reduced insulin-stimulated glucose oxidation compared with low fat–fed WT mice (167 ± 31 vs. 734 ± 125; P < 0.05). MCD−/− mice subjected to DIO displayed a more robust insulin-stimulated glucose oxidation (554 ± 82 vs. 167 ± 31; P < 0.05) and less incomplete fatty acid oxidation, evidenced by a decrease in long-chain acylcarnitines compared with WT counterparts. MCD−/− mice had long-chain acyl CoAs similar to those of WT mice subjected to DIO but had increased triacylglycerol levels (10.92 ± 3.72 vs. 3.29 ± 0.62 μmol/g wet wt; P < 0.05). CONCLUSIONS: DIO does not impair cardiac fatty acid oxidation or function, and there exists disassociation between myocardial lipid accumulation and insulin sensitivity. Our results suggest that MCD deficiency is not detrimental to the heart in obesity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Loss of MCD results in partial CPT1 inhibition [50,88].”
From Intramuscular triacylglycerol and insulin resistance: guilty as charged or wrongly accused? (2010) · cites this paper as [88]
In the citing paper
“the mcd−/− mice had decreased acylcarnitine accumulation in muscle, enhanced rates of glucose oxidation, and resisted diet-induced glucose intolerance, despite high intramuscular levels of triacylglycerol and long chain acyl-CoAs [50,88].”
From Intramuscular triacylglycerol and insulin resistance: guilty as charged or wrongly accused? (2010) · cites this paper as [88]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global Burden of Diabetes, 1995–2025: Prevalence, numerical estimates, and projections
King, H., Aubert, R. E., & Herman, W. H. (1998) · Diabetes Care · doi:10.2337/diacare.21.9.1414 · Cited by 6,311 · cited 1×
“The incidence of obesity, insulin resistance, and diabetes is rapidly increasing (1–4), and by 2025 it is estimated that worldwide the incidence of diabetes will affect nearly 333 million individuals between 20 and 79 years of age (4).”
BackgroundCellular mechanisms of insulin resistance
Shulman, G. I. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10583 · Cited by 2,714
Koves, T. R., Ussher, J. R., Noland, R. C., Slentz, D., Mosedale, M., Ilkayeva, O., Bain, J., Stevens, R., Dyck, J. R. B., Newgard, C. B., et al. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2007.10.013 · Cited by 1,990 · cited 10×
“Recent studies have suggested that accumulation of intermediates of incomplete fatty acid oxidation correlate with skeletal muscle insulin resistance (11,25,26).”
BackgroundMethodResultInfluentialSelf-citationThe worldwide obesity epidemic
James, P. T., Leach, R., Kalamara, E., & Shayeghi, M. (2001) · Obesity Research · doi:10.1038/oby.2001.123 · Cited by 1,201 · cited 1×
“3 he incidence of obesity, insulin resistance, and diabetes is rapidly increasing (1-4), and by 2025 it is estimated that worldwide the incidence of diabetes will affect nearly 333 million individuals between 20 and 79 years of age (41).”
BackgroundGoodpaster, B. H. (2001) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.12.5755 · Cited by 1,194 · cited 1×
“Further support for this concept lies in the athletes’ paradox, in which endurance-trained individuals have greater muscle insulin sensitivity despite greater levels of intramuscular triacylglycerols (38,39).”
BackgroundMolecular and metabolic mechanisms of insulin resistance and β-cell failure in type 2 diabetes
Muoio, D. M., & Newgard, C. B. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2327 · Cited by 1,177
Self-citationDisordered lipid metabolism and the pathogenesis of insulin resistance.
Savage, D. B., Petersen, K. F., & Shulman, G. I. (2007) · Physiological Reviews · doi:10.1152/physrev.00024.2006 · Cited by 1,107 · cited 1×
“While there is a general consensus that increased circulating fatty acids lead to increased rates of fatty acid uptake in muscle, the contribution of impaired mitochondrial fatty acid oxidation to the accumulation of cytosolic intramuscular fatty acid metabolites implicated in the pathogenesis of insulin resistance (s…”
BackgroundThe cardiac phenotype induced by PPARα overexpression mimics that caused by diabetes mellitus
Finck, B. N., Lehman, J. J., Leone, T. C., Welch, M. J., Bennett, M. J., Kovács, A. D., Han, X., Gross, R. W., Kozak, R., Lopaschuk, G. D., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci14080 · Cited by 879
Self-citationUnger, R. H. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.104057 · Cited by 875 · cited 1×
“While there is a general consensus that increased circulating fatty acids lead to increased rates of fatty acid uptake in muscle, the contribution of impaired mitochondrial fatty acid oxidation to the accumulation of cytosolic intramuscular fatty acid metabolites implicated in the pathogenesis of insulin resistance (s…”
BackgroundEtiology of Insulin Resistance
Petersen, K. F., & Shulman, G. I. (2006) · The American Journal of Medicine · doi:10.1016/j.amjmed.2006.01.009 · Cited by 825 · cited 2×
“It has been suggested that an impairment in the mitochondrial uptake and subsequent oxidation of fatty acids contribute to the accumulation of intramuscular acyl CoAs and the development of insulin resistance (6,8,15) and myocardial dysfunction (16,17,20).”
Background
Cited by
Myocardial Fatty Acid Metabolism in Health and Disease
Lopaschuk, G. D., Ussher, J. R., Folmes, C. D. L., Jaswal, J. S., & Stanley, W. C. (2010) · Physiological Reviews · doi:10.1152/physrev.00015.2009 · Cited by 2,179
Self-citationCardiac Energy Metabolism in Heart Failure
Lopaschuk, G. D., Karwi, Q. G., Tian, R., Wende, A. R., & Abel, E. D. (2021) · Circulation Research · doi:10.1161/circresaha.121.318241 · Cited by 1,373
Self-citationMitochondrial dysfunction in pathophysiology of heart failure
Zhou, B., & Tian, R. (2018) · Journal of Clinical Investigation · doi:10.1172/jci120849 · Cited by 923
“Moreover, incomplete fatty acid oxidation has been implicated in the development of insulin resistance in skeletal muscle, although similar studies in the heart are lacking (63, 64).”
BackgroundCardiac Metabolism and its Interactions With Contraction, Growth, and Survival of Cardiomyocytes
Kolwicz, S. C., Purohit, S., & Tian, R. (2013) · Circulation Research · doi:10.1161/circresaha.113.302095 · Cited by 813
Acylcarnitines: Nomenclature, Biomarkers, Therapeutic Potential, Drug Targets, and Clinical Trials
Dambrova, M., Makrecka-Kuka, M., Kuka, J., Vilskersts, R., Nordberg, D., Attwood, M. M., Smesny, S., Sen, Z. D., Guo, A. C., Oler, E., et al. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.121.000408 · Cited by 507
“In healthy subjects, the increased concentration of insulin effectively inhibits long-chain acylcarnitine production via the increased tissue content of malonylCoA (Koves et al., 2008; Ussher et al., 2009).”
BackgroundLoss of Metabolic Flexibility in the Failing Heart
Karwi, Q. G., Uddin, G. M., Ho, K. L., & Lopaschuk, G. D. (2018) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2018.00068 · Cited by 442
Self-citationAnderson, E. J., Kypson, A. P., Rodriguez, E., Anderson, C. A., Lehr, E. J., & Neufer, P. D. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.07.031 · Cited by 440
Jaswal, J. S., Keung, W., Wang, W., Ussher, J. R., & Lopaschuk, G. D. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.01.015 · Cited by 400
Self-citationThe Emerging Role of Metabolomics in the Diagnosis and Prognosis of Cardiovascular Disease
Ussher, J. R., Elmariah, S., Gerszten, R. E., & Dyck, J. R. B. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.09.972 · Cited by 358
Self-citationKolwicz, S. C., Olson, D. P., Marney, L. C., Garcia-Menendez, L., Synovec, R. E., & Tian, R. (2012) · Circulation Research · doi:10.1161/circresaha.112.268128 · Cited by 288
Assessing Cardiac Metabolism: A Scientific Statement From the American Heart Association
Taegtmeyer, H., Young, M. E., Lopaschuk, G. D., Abel, E. D., Brunengraber, H., Darley-Usmar, V., Des Rosiers, C., Gerszten, R., Glatz, J. F., Griffin, J. L., et al. (2016) · Circulation Research · doi:10.1161/res.0000000000000097 · Cited by 286
Self-citationZhang, L., Jaswal, J. S., Ussher, J. R., Sankaralingam, S., Wagg, C., Zaugg, M., & Lopaschuk, G. D. (2013) · Circulation: Heart Failure · doi:10.1161/circheartfailure.112.000228 · Cited by 269
“Determination of pyruvate dehydrogenase activity was performed as described previously.(21)”
MethodSelf-citationMitochondrial and cellular mechanisms for managing lipid excess
Aon, M. A., Bhatt, N., & Cortassa, S. C. (2014) · Frontiers in Physiology · doi:10.3389/fphys.2014.00282 · Cited by 253
“In skeletal (Liu et al., 2007) and cardiac (Ussher et al., 2009) muscle, IMCL accumulation as a result of diet-induced obesity is not at all pathogenic, but may even be protective against obesity-associated maladies.”
BackgroundAlrob, O. A., Sankaralingam, S., Ma, C., Wagg, C. S., Fillmore, N., Jaswal, J. S., Sack, M. N., Lehner, R., Gupta, M. P., Michelakis, E. D., et al. (2014) · Cardiovascular Research · doi:10.1093/cvr/cvu156 · Cited by 221
Self-citationLipid metabolism and signaling in cardiac lipotoxicity
D'Souza, K., Nzirorera, C., & Kienesberger, P. C. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2016.02.016 · Cited by 188
Mori, J., Patel, V. B., Abo Alrob, O., Basu, R., Altamimi, T., DesAulniers, J., Wagg, C. S., Kassiri, Z., Lopaschuk, G. D., & Oudit, G. Y. (2014) · Circulation: Heart Failure · doi:10.1161/circheartfailure.113.000672 · Cited by 192
“High rates of myocardial fatty acid β-oxidation play a key role in the pathogenesis of diabetic cardiomyopathy, including the db/db model.(28,29) Although Ang II/Ang II type 1 receptor represents a key driver of metabolic perturbations and diastolic abnormalities,(11,19) Ang 1–7/MasR is considered a physiological anta…”
BackgroundSelf-citationMolecular and metabolic mechanisms of cardiac dysfunction in diabetes
Mandavia, C. H., Aroor, A. R., DeMarco, V. G., & Sowers, J. R. (2013) · Life Sciences · doi:10.1016/j.lfs.2012.10.028 · Cited by 190
Stimulation of glucose oxidation protects against acute myocardial infarction and reperfusion injury
Ussher, J. R., Wang, W., Gandhi, M., Keung, W., Samokhvalov, V., Oka, T., Wagg, C. S., Jaswal, J. S., Harris, R. A., Clanachan, A. S., et al. (2012) · Cardiovascular Research · doi:10.1093/cvr/cvs129 · Cited by 185
Self-citationCherian, S., Lopaschuk, G. D., & Carvalho, E. (2012) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00061.2012 · Cited by 185
“This development of insulin resistance in the heart correlates with the accumulation of diacylglycerol (DAG) in the heart and not long-chain acyl-CoA, ceramides, or TG accumulation (136, 153).”
BackgroundSelf-citationLipotoxicity in obesity and diabetes-related cardiac dysfunction
Zlobine, I., Gopal, K., & Ussher, J. R. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2016.02.011 · Cited by 168
“CPT-1-mediated conversion of long-chain acyl CoAs produces long-chain acylcarnitines that can enter the mitochondria, and a number of studies have shown that both experimental obesity or diabetes increase myocardial long-chain acylcarnitine levels [48,119,120].”
BackgroundResultInfluentialSelf-citationMori, J., Basu, R., McLean, B. A., Das, S. K., Zhang, L., Patel, V. B., Wagg, C. S., Kassiri, Z., Lopaschuk, G. D., & Oudit, G. Y. (2012) · Circulation: Heart Failure · doi:10.1161/circheartfailure.112.966705 · Cited by 170
“We extracted nuclear and cytoplasmic proteins, and Western blotting analyses were performed, as described previously.(18,23)”
MethodSelf-citationMitochondrial NAD + /NADH Redox State and Diabetic Cardiomyopathy
Berthiaume, J. M., Kurdys, J. G., Muntean, D. M., & Rosca, M. G. (2019) · Antioxidants & Redox Signaling · doi:10.1089/ars.2017.7415 · Cited by 168
“Similarly, HFD led to increased lysine acetylation of FA oxidation enzymes and long chain acylCoA dehydrogenase, LCAD, activation, thus enhancing cardiac FA oxidation (6).”
InfluentialBasu, R., Oudit, G. Y., Wang, X., Zhang, L., Ussher, J. R., Lopaschuk, G. D., & Kassiri, Z. (2009) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00452.2009 · Cited by 161
“Intramyocardial lipids were extracted from 5 mg of flash-frozen freshly excised heart tissue (not perfused), as described previously (45).”
MethodSelf-citationZhabyeyev, P., Gandhi, M., Mori, J., Basu, R., Kassiri, Z., Clanachan, A. S., Lopaschuk, G. D., & Oudit, G. Y. (2012) · Cardiovascular Research · doi:10.1093/cvr/cvs424 · Cited by 162
Self-citationTargeting mitochondrial oxidative metabolism as an approach to treat heart failure
Fillmore, N., & Lopaschuk, G. D. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2012.08.014 · Cited by 158
Self-citationCardiac fatty acid oxidation in heart failure associated with obesity and diabetes
Fukushima, A., & Lopaschuk, G. D. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2016.03.020 · Cited by 153
Self-citationIntramuscular triacylglycerol and insulin resistance: guilty as charged or wrongly accused?
Muoio, D. M. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2009.11.007 · Cited by 137
“Loss of MCD results in partial CPT1 inhibition [50,88].”
BackgroundSelf-citationRueda-Clausen, C. F., Dolinsky, V. W., Morton, J. S., Proctor, S. D., Dyck, J. R. B., & Davidge, S. T. (2011) · Diabetes · doi:10.2337/db10-1239 · Cited by 132
“to receive either a low-fat (LF) diet (10% fat, Research Diets D12450B) or a HF diet (45% fat, Research Diets D12451) as we and other groups (25,26) have previously described (detailed diet compositions are given in Supplementary Table 1).”
MethodSelf-citationFillmore, N., Levasseur, J. L., Fukushima, A., Wagg, C. S., Wang, W., Dyck, J. R. B., & Lopaschuk, G. D. (2018) · Molecular Medicine · doi:10.1186/s10020-018-0005-x · Cited by 133
“At the end of the aerobic perfusion protocol, hearts were immediately frozen in liquid N2 and stored at − 80 °C (Barr and Lopaschuk 1997; Ussher et al. 2009).”
Self-citationZhang, L., Ussher, J. R., Oka, T., Cadete, V. J. J., Wagg, C., & Lopaschuk, G. D. (2011) · Cardiovascular Research · doi:10.1093/cvr/cvq266 · Cited by 129
Self-citationKeung, W., Ussher, J. R., Jaswal, J. S., Raubenheimer, M., Lam, V. H. M., Wagg, C. S., & Lopaschuk, G. D. (2013) · Diabetes · doi:10.2337/db12-0259 · Cited by 128
“However, we observed no change in the phosphorylation of JNK and IKK in oxfenicine-treated DIO mice (Supplementary Fig.”
BackgroundInfluentialSelf-citationRuggiero, C., Ehrenshaft, M., Cleland, E., & Stadler, K. (2011) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00666.2010 · Cited by 122
Impact of peroxisome proliferator-activated receptor-α on diabetic cardiomyopathy
Wang, L., Cai, Y., Jian, L., Cheung, C. W., Zhang, L., & Xia, Z. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01188-0 · Cited by 120
Self-citationAbdurrachim, D., Luiken, J. J. F. P., Nicolay, K., Glatz, J. F. C., Prompers, J. J., & Nabben, M. (2015) · Cardiovascular Research · doi:10.1093/cvr/cvv105 · Cited by 120
“However, in contrast to wild-type mice, high-fat diet (HFD) feeding did not increase FAO in MCD-KO mice, which prevented accumulation of metabolic intermediates of incomplete FAO, resulting in protection against HFD-induced cardiac dysfunction.(28) Another study recently reported that deletion of MCD did, however, res…”
BackgroundKienesberger, P. C., Pulinilkunnil, T., Sung, M. M. Y., Nagendran, J., Haemmerle, G., Kershaw, E. E., Young, M. E., Light, P. E., Oudit, G. Y., Zechner, R., et al. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.06470-11 · Cited by 119
“scribed previously (11, 47), and sn-1,2-diacylglycerol content was deter-”
Self-citationUssher, J. R., Campbell, J. E., Mulvihill, E. E., Baggio, L. L., Bates, H. E., McLean, B. A., Gopal, K., Capozzi, M. E., Yusta, B., Cao, X., et al. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.11.003 · Cited by 107
Self-citationMasoud, W. G. T., Ussher, J. R., Wang, W., Jaswal, J. S., Wagg, C. S., Dyck, J. R. B., Lygate, C. A., Neubauer, S., Clanachan, A. S., & Lopaschuk, G. D. (2013) · Cardiovascular Research · doi:10.1093/cvr/cvt216 · Cited by 103
Self-citationRole of CoA and acetyl-CoA in regulating cardiac fatty acid and glucose oxidation
Alrob, O. A., & Lopaschuk, G. D. (2014) · Biochemical Society Transactions · doi:10.1042/bst20140094 · Cited by 103
Self-citationKetones can become the major fuel source for the heart but do not increase cardiac efficiency
Ho, K. L., Karwi, Q. G., Wagg, C. S., Zhang, L., Vo, K., Altamimi, T., Uddin, G. M., Ussher, J. R., & Lopaschuk, G. D. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvaa143 · Cited by 96
“Insulin is an important regulator of energy metabolism in the heart, with increasing insulin concentrations resulting in an increase in glucose oxidation (Figure 1C,G) and a decrease in fatty acid oxidation (Figure 1B,F).(2,34) In contrast, at lower concentrations of ketones, insulin had no effect on ketone oxidation…”
BackgroundSelf-citationPyridine Nucleotide Regulation of Cardiac Intermediary Metabolism
Ussher, J. R., Jaswal, J. S., & Lopaschuk, G. D. (2012) · Circulation Research · doi:10.1161/circresaha.111.246371 · Cited by 98
Self-citationFukushima, A., & Lopaschuk, G. D. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2016.07.020 · Cited by 103
Self-citationGuidelines on models of diabetic heart disease
Heather, L. C., Hafstad, A. D., Halade, G. V., Harmancey, R., Mellor, K. M., Mishra, P. K., Mulvihill, E. E., Nabben, M., Nakamura, M., Rider, O. J., et al. (2022) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00058.2022 · Cited by 97
“This includes alterations in cardiac metabolism [e.g., decreased glucose oxidation and increased fatty acid oxidation (53, 65, 72, 73)], cardiac lipotoxicity [e.g., ceramide and/ or diacylglycerol (DAG) accumulation (63, 67, 74)], in fl am-mation (75), microvascular dysfunction (76), and endoplasmic…”
BackgroundSelf-citationAlmutairi, M., Gopal, K., Greenwell, A. A., Young, A., Gill, R., Aburasayn, H., Al Batran, R., Chahade, J. J., Gandhi, M., Eaton, F., et al. (2021) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2020.02.098 · Cited by 72
Self-citationSankaralingam, S., Abo Alrob, O., Zhang, L., Jaswal, J. S., Wagg, C. S., Fukushima, A., Padwal, R. S., Johnstone, D. E., Sharma, A. M., & Lopaschuk, G. D. (2015) · Diabetes · doi:10.2337/db14-1050 · Cited by 75
Self-citationBatran, R. A., Gopal, K., Capozzi, M. E., Chahade, J. J., Saleme, B., Dakhili, S. A. T., Greenwell, A. A., Niu, J., Almutairi, M. G., Byrne, N. J., et al. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.03.017 · Cited by 79
Self-citationGopal, K., Saleme, B., Batran, R. A., Aburasayn, H., Eshreif, A., Ho, K. L., Ma, W. K., Almutairi, M. G., Eaton, F., Gandhi, M., et al. (2017) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00191.2017 · Cited by 80
“Intriguingly, interventions that promote glucose oxidation have been shown to improve the pathophysiology of these cardiovascular diseases, which are potentially due to enhancing cardiac efficiency, as glucose is the more efficient fuel compared with fatty acids such as oleate and palmitate with regard to ATP produced…”
BackgroundSelf-citationCardiac branched-chain amino acid oxidation is reduced during insulin resistance in the heart
Fillmore, N., Wagg, C. S., Zhang, L., Fukushima, A., & Lopaschuk, G. D. (2018) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00097.2018 · Cited by 81
Self-citationLipotoxicity: a driver of heart failure with preserved ejection fraction?
Leggat, J., Bidault, G., & Vidal‐Puig, A. (2021) · Clinical Science · doi:10.1042/cs20210127 · Cited by 77
Updating Experimental Models of Diabetic Cardiomyopathy
Fuentes‐Antrás, J., Picatoste, B., Gómez‐Hernández, A., Egido, J., Tuñón, J., & Lorenzo, Ó. (2015) · Journal of Diabetes Research · doi:10.1155/2015/656795 · Cited by 76
“found increased FAO rates [73], though Ussher’s group observed no association between lipid accumulation and insulin sensitivity [74].”
Abdurrachim, D., Čiapaitė, J., Wessels, B., Nabben, M., Luiken, J. J. F. P., Nicolay, K., & Prompers, J. J. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2014.07.016 · Cited by 76
Gopal, K., Batran, R. A., Altamimi, T., Greenwell, A. A., Saed, C. T., Dakhili, S. A. T., Dimaano, M. T. E., Zhang, Y., Eaton, F., Sutendra, G., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.108935 · Cited by 71
Self-citationAli, S., Ussher, J. R., Baggio, L. L., Kabir, M. G., Charron, M. J., Ilkayeva, O., Newgard, C. B., & Drucker, D. J. (2015) · Molecular Metabolism · doi:10.1016/j.molmet.2014.11.005 · Cited by 69
Self-citationBranched-Chain Amino Acid Metabolism in the Failing Heart
Karwi, Q. G., & Lopaschuk, G. D. (2022) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-022-07320-4 · Cited by 69
Self-citationRegulation and dysregulation of glucose transport in cardiomyocytes
Montessuit, C., & Lerch, R. A. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2012.08.009 · Cited by 74
“Recent evidence suggests that lipid intermediates originating from incomplete fatty acid oxidation could induce insulin resistance in the skeletal muscle [151] and in the heart [157].”
The role of Pyruvate Dehydrogenase Complex in cardiovascular diseases
Sun, W., Liu, Q., Leng, J., Zheng, Y., & Li, J. (2014) · Life Sciences · doi:10.1016/j.lfs.2014.11.030 · Cited by 64
Influence of dark phase restricted high fat feeding on myocardial adaptation in mice
Tsai, J.-Y., Villegas-Montoya, C., Boland, B. B., Blasier, Z., Egbejimi, O., Gonzalez, R., Kueht, M., McElfresh, T. A., Brewer, R. A., Chandler, M. P., et al. (2013) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2012.09.010 · Cited by 62
“For example, feeding C57/Bl6 mice a high fat diet for up to 12 weeks does not appear to adversely affect myocardial contractile function, despite development of marked obesity [13].”
MethodMy Sweetheart Is Broken: Role of Glucose in Diabetic Cardiomyopathy
Brahma, M. K., Pepin, M. E., & Wende, A. R. (2017) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2017.41.1.1 · Cited by 64
“Also, a mouse model with cardiac deficiency of malonyl-CoA decarboxylase, an enzyme promoting mitochondrial fatty acid oxidation, demonstrates that reduced fatty acid oxidation restored cardiac glucose oxidation in mice on high fat diet [22].”
BackgroundLysine Malonylation and Its Links to Metabolism and Diseases
Zou, L., Yang, Y., Wang, Z., Fu, X., He, X., Song, J., Li, T., Ma, H., & Yu, T. (2022) · Aging and Disease · doi:10.14336/ad.2022.0711 · Cited by 64
Wu, Y.-T., Wu, S.-B., & Wei, Y.-H. (2014) · Free Radical Research · doi:10.3109/10715762.2014.920956 · Cited by 56
Myocardial Metabolism in Diabetic Cardiomyopathy: Potential Therapeutic Targets
Sung, M. M. Y., Hamza, S. M., & Dyck, J. R. B. (2015) · Antioxidants and Redox Signaling · doi:10.1089/ars.2015.6305 · Cited by 59
“However, we have shown that increased cardiac expression of ATGL is associated with elevated TAG levels in mouse models of T1D (211) and HFD-induced T2D (210).”
InfluentialSelf-citationThe role of cardiac lipotoxicity in the pathogenesis of diabetic cardiomyopathy
Ussher, J. R. (2014) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2014.891939 · Cited by 59
“Similar findings have been reproduced in the heart, as high fat diet fed mice lacking malonyl CoA decarboxylase, the enzyme responsible for degrading malonyl CoA (potent endogenous inhibitor of carnitine palmitoyltransferase 1-mediated mitochondrial fatty acid uptake [71,72]), exhibit a significant reduction in myocar…”
BackgroundSelf-citationCrewe, C., Kinter, M. T., & Szweda, L. I. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077280 · Cited by 57
“In fact, malonyl-CoA decarboxylase knockout (MCD -/- ) mice that exhibit diminished cardiac β-oxidation do not undergo diet-induced loss of cardiac insulin sensitivity and glucose utilization and are protected from cardiac ischemia and reperfusion injury [31,32].”
BackgroundRedox regulation of insulin sensitivity due to enhanced fatty acid utilization in the mitochondria
Rindler, P. M., Crewe, C. L., Fernandes, J., Kinter, M., & Szweda, L. I. (2013) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00799.2012 · Cited by 54
Periodontitis and mechanisms of cardiometabolic risk: Novel insights and future perspectives
Mesa, F., Magán‐Fernández, A., Castellino, G., Chianetta, R., Nibali, L., & Rizzo, M. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.12.001 · Cited by 59
Ussher, J. R., Folmes, C. D. L., Keung, W., Fillmore, N., Jaswal, J. S., Cadete, V. J. J., Beker, D. L., Lam, V. H., Zhang, L., & Lopaschuk, G. D. (2012) · PLoS ONE · doi:10.1371/journal.pone.0037703 · Cited by 51
Self-citationSun, W., Quan, N., Wang, L., Yang, H. M., Chu, D., Liu, Q., Zhao, X., Leng, J., & Li, J. (2016) · Toxicological Sciences · doi:10.1093/toxsci/kfw035 · Cited by 48
Jeong, J. Y., Bong, J. J., Kim, G. D., Joo, S.-T., Lee, H.-J., & Baik, M. (2013) · Journal of Animal Science · doi:10.2527/jas.2012-6089 · Cited by 50
Rueda‐Clausen, C. F., Morton, J. S., Dolinsky, V. W., Dyck, J. R. B., & Davidge, S. T. (2012) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00148.2012 · Cited by 47
Self-citationGopal, K., Karwi, Q. G., Dakhili, S. A. T., Wagg, C. S., Zhang, L., Sun, Q., Saed, C. T., Panidarapu, S., Perfetti, R., Ramasamy, R., et al. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01811-w · Cited by 43
“A plethora of preclinical and clinical studies have characterized the metabolic perturbations in type 2 diabetes, which includes impaired glucose oxidation and increased fatty acid oxidation, which has been observed in HFDfed mice [14], as well as db/db and ob/ob mice [11].”
BackgroundSelf-citationMyocardial Energy Metabolism in Non-ischemic Cardiomyopathy
Greenwell, A. A., Gopal, K., & Ussher, J. R. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.570421 · Cited by 43
Self-citationGopal, K., Almutairi, M. G., Batran, R. A., Eaton, F., Gandhi, M., & Ussher, J. R. (2018) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2018.00017 · Cited by 42
“These preclinical findings appear to translate to the clinical scenario, as PET imaging studies in either obese women or men with T2D demonstrate marked increases in myocardial fatty acid oxidation rates and a decline in glucose utilization (7, 20).”
BackgroundSelf-citationMingorance, C., Duluc, L., Chalopin, M., Simard, G., Ducluzeau, P., Herrera, M. D., de Sotomayor, M. Á., & Andriantsitohaina, R. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034268 · Cited by 42
Holloway, G. P., Snook, L. A., Harris, R. J., Glatz, J. F. C., Luiken, J. J. F. P., & Bonen, A. (2010) · The Journal of Physiology · doi:10.1113/jphysiol.2010.198663 · Cited by 45
“…of acid-soluble intermediates to CO2 production have previously been used to infer incomplete oxidation of fatty acids and mitochondrial dysfunction (i.e. an imbalance between TCA and ETC fluxes) in skeletal (Koves et al. 2008) and cardiac (Ussher et al. 2009) muscle of insulin-resistant animals.”
BackgroundKerr, M. J., Dodd, M. S., & Heather, L. C. (2017) · Clinical Science · doi:10.1042/cs20160671 · Cited by 44
Liepinsh, E., Makrecka‐Kuka, M., Makarova, E., Volska, K., Vilks, K., Sevostjanovs, E., Antone, U., Kuka, J., Vilšķe̅rsts, R., Loļa, D., et al. (2017) · BioFactors · doi:10.1002/biof.1378 · Cited by 43
Trimetazidine Therapy Prevents Obesity-Induced Cardiomyopathy in Mice
Ussher, J. R., Fillmore, N., Keung, W., Mori, J., Beker, D. L., Wagg, C. S., Jaswal, J. S., & Lopaschuk, G. D. (2014) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2014.04.023 · Cited by 39
Self-citationAnimal Models of Dysregulated Cardiac Metabolism
Bugger, H., Byrne, N. J., & Abel, E. D. (2022) · Circulation Research · doi:10.1161/circresaha.122.320334 · Cited by 37
Kramer, S. P., Powell, D. K., Haggerty, C. M., Friday, C. M., Mattingly, A. C., Cassis, L. A., Epstein, F. H., & Fornwalt, B. K. (2013) · Journal of Cardiovascular Magnetic Resonance · doi:10.1186/1532-429x-15-109 · Cited by 40
“For example, some studies have shown cardiac dysfunction in mouse models of obesity [9-16], while others have shown no dysfunction [17-24].”
Rindler, P. M., Cacciola, A., Kinter, M. T., & Szweda, L. I. (2016) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00066.2016 · Cited by 39
Wang, X., West, J. A., Murray, A. J., & Griffin, J. L. (2015) · Journal of Proteome Research · doi:10.1021/acs.jproteome.5b00128 · Cited by 36
Ketone Body Metabolism in the Ischemic Heart
Kolwicz, S. C. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.789458 · Cited by 32
“Research studies have uncovered critical changes in cardiac substrate metabolism under conditions of stress, especially in pathological hypertrophy (12, 13), heart failure (14, 15), ischemiareperfusion (16–18), and obesity/diabetes (19, 20).”
BackgroundSamokhvalov, V., Ussher, J. R., Fillmore, N., Armstrong, I. K. G., Keung, W., Moroz, D., Lopaschuk, D. G., Seubert, J. M., & Lopaschuk, G. D. (2012) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00018.2012 · Cited by 32
Self-citationComprehensive Analysis of Mitochondrial Dynamics Alterations in Heart Diseases
Morciano, G., Boncompagni, C., Ramaccini, D., Pedriali, G., Bouhamida, E., Tremoli, E., Giorgi, C., & Pinton, P. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043414 · Cited by 31
“However, this balance in cardiac energy metabolism could be gradually shifted in pathological conditions, resulting in an energy crisis, mitigating cardiac activity, and it is believed to contribute to multiple heart disorders [21,22].”
Malonyl CoA: A promising target for the treatment of cardiac disease
Fillmore, N., & Lopaschuk, G. D. (2014) · IUBMB Life · doi:10.1002/iub.1253 · Cited by 33
“Unlike Fillmore and Lopaschuk 141 diabetes, cardiac malonyl CoA levels are not altered in the hearts of obese mice fed a HFD (58,62).”
BackgroundInfluentialSelf-citationBrar, A. S., Khanna, T., Sohal, A., Hatwal, J., Sharma, V., Singh, C. M., Batta, A., Chandra, P., & Mohan, B. (2026) · World Journal of Cardiology · doi:10.4330/wjc.v18.i1.111954 · Cited by 30
“In mice that lack malonyl-CoA decarboxylase, a fatty diet did not lead to cardiac dysfunction, possibly due to low levels of acylcarnitines, i.e. toxic lipid intermediaries[92].”
Aksentijević, D., McAndrew, D. J., Karlstaedt, A., Zervou, S., Sebag‐Montefiore, L., Cross, R., Douglas, G., Regitz‐Zagrosek, V., Lopaschuk, G. D., Neubauer, S., et al. (2014) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2014.07.008 · Cited by 29
Self-citationPoncelas, M., Inserte, J., Vilardosa, Ú., Rodríguez‐Sinovas, A., Bañeras, J., Simó, R., & García‐Dorado, D. (2015) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2015.04.023 · Cited by 28
Glucagon-like peptide-1 receptor mediated control of cardiac energy metabolism
Batran, R. A., Almutairi, M. G., & Ussher, J. R. (2018) · Peptides · doi:10.1016/j.peptides.2017.12.005 · Cited by 28
Self-citationHo, K. L., Karwi, Q. G., Wang, F., Wagg, C. S., Zhang, L., Panidarapu, S., Chen, B., Pherwani, S., Greenwell, A. A., Oudit, G. Y., et al. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvae092 · Cited by 24
Self-citationZheng, Z., Ma, T., Guo, H., Kim, K. S., Kim, K., Bi, L., Zhang, Z., & Cai, L. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14493 · Cited by 24
Davies, A. J., Wenzl, F. A., Li, X. S., Winzap, P., Obeid, S., Klingenberg, R., Mach, F., Räber, L., Müller, O., Matter, C. M., et al. (2023) · International Journal of Cardiology · doi:10.1016/j.ijcard.2023.131261 · Cited by 22
The Impact of Current and Novel anti-diabetic Therapies On Cardiovascular Risk
Ussher, J. R., Sutendra, G., & Jaswal, J. S. (2012) · Future Cardiology · doi:10.2217/fca.12.68 · Cited by 21
“(2012) 8(6) 904 future science group obesity-induced cardiac insulin resistance, which is associated with a marked reduction in intramyocardial diacylglycerol content [134,135].”
BackgroundSelf-citationElnwasany, A., Ewida, H. A., Szweda, P. A., & Szweda, L. I. (2023) · Antioxidants · doi:10.3390/antiox12030756 · Cited by 22
Peng, S., Wang, Y., Zhou, Y., Ma, T., Wang, Y., Li, J., Huang, F., Kou, J., Qi, L., Liu, B., et al. (2018) · Phytomedicine · doi:10.1016/j.phymed.2018.11.006 · Cited by 20
Keung, W., Cadete, V. J. J., Palaniyappan, A., Jablonski, A., Fischer, M. A., & Lopaschuk, G. D. (2010) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e31820014f9 · Cited by 18
“Glucose oxidation is decreased in the hearts of high-fat– fed mice compared with the low-fat–fed mice, which is in accord with previous studies.(46) Our findings show that in lowfat–fed mice, ICV leptin increases myocardial glucose oxidation.”
ResultSelf-citationStimulating cardiac glucose oxidation lessens the severity of heart failure in aged female mice
Sun, Q., Wagg, C. S., Güven, B., Wei, K., de Oliveira, A. A., Silver, H. L., Zhang, L., Vergara, A., Chen, B., Wong, N. K. P., et al. (2023) · Basic Research in Cardiology · doi:10.1007/s00395-023-01020-2 · Cited by 17
“Additionally, mice that are fed with a HFD for 8-weeks also have markedly impaired glucose oxidation rates [53].”
Self-citationBarth syndrome-related cardiomyopathy is associated with a reduction in myocardial glucose oxidation
Greenwell, A. A., Gopal, K., Altamimi, T., Saed, C. T., Wang, F., Dakhili, S. A. T., Ho, K. L., Zhang, L., Eaton, F., Kruger, J., et al. (2021) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00873.2020 · Cited by 17
Self-citationUssher, J. R., Fillmore, N., Keung, W., Zhang, L., Mori, J., Sidhu, V. K., Fukushima, A., Gopal, K., Lopaschuk, D. G., Wagg, C. S., et al. (2016) · Diabetes · doi:10.2337/db15-1145 · Cited by 17
“3 mL saline solution, while long-chain acyl CoA was extracted in 200 mL of cold 100 mmol/L KH2PO4 for high-performance liquid chromatography (HPLC) analysis as previously described (8,12).”
BackgroundMethodResultInfluentialSelf-citationZhang, X., Liu, S., Zhang, G., Zhong, M., Liu, T., Wei, M., Wu, D., Huang, X., Cheng, Y., Wu, Q., et al. (2016) · Obesity Surgery · doi:10.1007/s11695-016-2492-6 · Cited by 15
Fillmore, N., Keung, W., Kelly, S. E., Proctor, S. D., Lopaschuk, G. D., & Ussher, J. R. (2015) · Experimental Physiology · doi:10.1113/ep085052 · Cited by 15
Self-citation
Metadata
- Authors
- Ussher, J. R., Koves, T. R., Jaswal, J. S., Zhang, L., Ilkayeva, O., Dyck, J. R. B., Muoio, D. M., & Lopaschuk, G. D.
- Affiliations
- University of Alberta (CA)
- Duke University (US)
- Corresponding author
- Lopaschuk, Gary D.
- ORCID
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2009-05-28
- Volume
- 58
- Issue
- 8
- Pages
- 1766-1775
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC2712785
- OpenAlex
- W2098822834
- Cited by
- 135
- References
- 45
- Citations by year
- 2026: 4 · 2025: 6 · 2024: 3 · 2023: 6 · 2022: 6 · 2021: 7 · 2020: 5 · 2019: 2 · 2018: 9 · 2017: 7 · 2016: 11 · 2015: 8 · 2014: 19 · 2013: 9 · 2012: 18
- FWCI
- 7.15
- Type
- journal article
- Language
- en
- Update notices
- correction (2009-10-01)
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Lipid metabolism and biosynthesis
- Keywords
- malonyl-CoA decarboxylase, insulin resistance, diet-induced obesity, high-fat diet, fatty acid oxidation, myocardial lipid accumulation, triglycerides, acylcarnitines, acyl-CoA, myocardial energy metabolism, cardiac function
- MeSH terms
- Animals, Carboxy-Lyases, Dietary Fats, Glucose, Heart, Insulin, Mice, Obese, Myocardium, Mice, Knockout, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.